NEW YORK – PerkinElmer will distribute Shuwen Biotech's diagnostic test for preeclampsia as part of a collaboration announced by Shuwen on Monday.
PerkinElmer will distribute the test in more than 100 countries, accounting for more than 120 million pregnancies each year. Further details of the deal were not disclosed.
The urine-based test, which was already available in several markets, does not require any specialized instrumentation and produces results in less than three minutes, Deqing, China-based Shuwen said in a statement, adding that the test has shown to be more than 95 percent accurate in diagnosing preeclampsia in women admitted to hospitals.